Companies › Acacia Pharma
1 active drug program in 12 registered trials: 11 Phase 4, 1 Phase 2; Cardiovascular, Gastroenterology, Infectious disease, Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Remimazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Pediatric ALL; Benzodiazepines; Cataract Surgery; Sedation for Diagnostic Gastroscopy … | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04532606 | Remimazolam | Phase 4 | Benzodiazepines | Oncology | Oct 2025 |
| NCT05980117 | Remimazolam | Phase 4 | Cataract Surgery | Ophthalmology | Dec 2025 |
| NCT06614036 | Remimazolam | Phase 4 | Sedation for Diagnostic Gastroscopy | Gastroenterology | Dec 2025 |
| NCT06784479 | Remimazolam | Phase 4 | Sedative Effect During Drug-induced Sleep Endoscopy | Respiratory | Mar 2026 |
| NCT07118579 | Remimazolam | Phase 4 | Tonsillectomy With or Without Adenoidectomy | Other | Aug 2026 |
| NCT07395596 | Remimazolam | Phase 4 | Pulmonary Infection | Infectious disease | Dec 2026 |
| NCT06777758 | Remimazolam | Phase 4 | Postoperative Complications | Psychiatry | Dec 2026 |
| NCT07046364 | Remimazolam | Phase 4 | Pediatric | Other | Jan 2027 |
| NCT07789275 | Remimazolam | Phase 4 | Intraoperative Hypotension | Cardiovascular | Jul 2027 |
| NCT07717684 | Remimazolam | Phase 4 | Intravenous Anesthesia | Gastroenterology | Aug 2027 |
| NCT04851717 | Remimazolam | Phase 2 | Pediatric ALL | Oncology | Oct 2027 |
| NCT05728775 | Remimazolam | Phase 4 | Anesthesia | Other | Dec 2027 |
Guangzhou Novaken Pharm Sedana Medical Lipocine Biocodex Ascension Health
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.